• Dawei Lu, Jie Yu, and Lin Sang.
• Dawei Lum, Department of Gynecology and Obstetrics, Hefei Second People's Hospital, Intersection of Guangde Road and Leshui Road, Hefei City, Anhui Province 230000, P.R. China.
• Pak J Med Sci. 2024 May 1; 40 (5): 870874870-874.

ObjectiveTo observe the treatment of severe preeclampsia in newborns with enoxaparin sodium combined with magnesium sulfate.MethodsA retrospective analysis was conducted on the clinical data of 80 patients with severe preeclampsia admitted to Hefei Second People's Hospital, China from January 2019 to December 2020. Treatment records showed that 40 cases received magnesium sulfate treatment (single group), and 40 cases received enoxaparin sodium combined with magnesium sulfate treatment (combination group). Levels of D-dimer, soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PLGF), Apgar scores of newborns delivered before and after treatment were compared. Gestation weeks and incidence of adverse reactions were analyzed.ResultsAfter treatment, levels of D-dimer, sfit-1 and adverse reactions in the combination group were significantly lower than those in the single group (P<0.05), and the level of PLGF, newborn Apgar score and length of gestation were significantly higher than those in the single group (P<0.05).ConclusionCompared to magnesium sulfate alone, the combination of enoxaparin sodium and magnesium sulfate in the treatment of pregnant women with severe preeclampsia can more effectively regulate the cytokine level of patients, improve pregnancy outcome, and improve neonatal Apgar score. The incidence of adverse reactions is low, making it a safe and efficient treatment modality.Copyright: © Pakistan Journal of Medical Sciences.

5 keywords...

hide…